多发性骨髓瘤中使用双特异性抗体相关的感染风险:一项汇总分析
该汇总分析纳入1185例多发性骨髓瘤患者,评估双特异性抗体(BsAbs)相关感染并发症。中位随访仅6.1个月,全级别感染发生率为50%,III/IV级感染为24.5%;与非BCMA靶向BsAbs相比,BCMA靶向BsAbs的III/IV级中性粒细胞减少(39.2% vs 25.3%)和III/IV级感染(30% vs 11.9%)更高。110例死亡中28例(25.5%)继发于感染。
要点
- 全级别感染发生率为50%(542/1083),III/IV级感染为24.5%(272/1110)。
- BCMA靶向BsAbs的III/IV级感染为30%,高于非BCMA靶向的11.9%。
- 110例死亡中28例(25.5%)继发于感染。
核心结论
- 使用BsAbs时应采取某些预防措施以降低风险并/或及时识别和治疗感染。
研究设计与样本
- 汇总分析纳入所有在多发性骨髓瘤中使用的单药BsAbs,且既往未使用不同BsAbs。
- 共1185例多发性骨髓瘤患者在研究期间接受BsAb治疗,其中71.6%接受靶向B细胞成熟抗原(BCMA)的药物。
- 汇总中位随访较短,为6.1个月(BCMA靶向 vs 非BCMA靶向分别为7.5个月 vs 5.2个月)。
主要发现
- 全级别中性粒细胞减少发生率为38.6%,全级别感染为50%(n=542/1083)。
- 全级别细胞因子释放综合征发生率为59.6%(n=706/1185),III/IV级中性粒细胞减少为34.8%(n=372/1068)。
- III/IV级感染发生率为24.5%(n=272/1110),III/IV级肺炎为10%(n=52.4/506),III/IV级冠状病毒病2019为11.4%(n=45.4/395)。
- 与非BCMA靶向BsAbs相比,BCMA靶向BsAbs的III/IV级中性粒细胞减少更高(39.2% vs 25.3%),III/IV级感染也更高(30% vs 11.9%)。
- 4项研究报告了低丙种球蛋白血症,患病率为75.3%(n=256/340),其中48%(n=123/256)使用了静脉注射免疫球蛋白。
关键数值与推荐
- 全级别感染:50%(n=542/1083)。
- III/IV级感染:24.5%(n=272/1110)。
- BCMA靶向BsAbs的III/IV级感染为30%,非BCMA靶向为11.9%。
- 低丙种球蛋白血症患病率75.3%(n=256/340),其中48%(n=123/256)使用静脉注射免疫球蛋白。
- 死亡110例,其中28例(25.5%)继发于感染。
临床怎么用
- 使用BsAbs时应采取某些预防措施以降低风险并/或及时识别和治疗感染。
局限性
- 汇总中位随访较短,为6.1个月(BCMA靶向 vs 非BCMA靶向分别为7.5个月 vs 5.2个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of bispecific antibodies (BsAbs) in the treatment of relapsed/refractory multiple myeloma (MM) is showing early promising overall response rates in heavily pretreated patients. Infectious complications related to the use of BsAbs are not well described. We conducted a pooled analysis that included all single-agent BsAbs used in MM with no prior use of different BsAbs. A total of 1185 patients with MM were treated with a BsAb in the studied period (71.6% of the patients treated with an agent targeting B-cell maturation antigen (BCMA). Pooled median follow-up was short at 6.1 months (7.5 vs 5.2 months for BCMA vs non-BCMA BsAbs, respectively). Adverse events of interest included all grade neutropenia in 38.6%, all grade infections in 50% (n = 542/1083), all grade cytokine release syndrome in 59.6% (n = 706/1185), grade III/IV neutropenia in 34.8% (n = 372/1068), grade III/IV infections in 24.5% (n = 272/1110), grade III/IV pneumonia in 10% (n = 52.4/506), and grade III/IV coronavirus disease 2019 in 11.4% (n = 45.4/395) of the patients. Non-BCMA-targeted BsAbs were associated with lower grade III/IV neutropenia (25.3% vs 39.2%) and lower grade III/IV infections (11.9% vs 30%) when compared with BCMA-targeted BsAbs. Hypogammaglobulinemia was reported in 4 studies, with a prevalence of 75.3% (n = 256/340) of the patients, with IV immunoglobulin used in 48% (n = 123/256) of them. Death was reported in 110 patients, of which 28 (25.5%) were reported to be secondary to infections. Certain precautions should be used when using BsAbs to mitigate the risk and/or identify and treat infections promptly.
引用
- Mazahreh F, Mazahreh L, Schinke C, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023. PMID: 36857755. doi:10.1182/bloodadvances.2022009435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。